高盛:予國壽(2628.HK)目標價26港元 評級“買入”
高盛研究報告指中國人壽(02628.HK)發盈喜,料去年純利按年大升介乎4至4.2倍,受惠投資收益及去年5月税務條例修訂。這意味去年國壽純利介乎570億至590億元人民幣(下同),略遜該行預期的650億元,但升幅未與該行預期有顯着差異。
報告稱,盈喜意味去年末季純利較小,介乎虧損7億元至錄純利16億元,由於去年12月股市表現強勁,高盛相信去年末季業績主要反映帳面上的股權投資未實現收益,倘實現,則料可於今年入賬。
高盛料其他受覆蓋的A股上市險商(平安、太保、新華保險及人保集團)將跟隨國壽步伐,在1月31日之前發盈喜。該行料該等保險商去年純利升幅達50%或以上。高盛予國壽目標價26港元,評級“買入”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.